Home /
Chemotherapy Treatment Details – Institut Gustave Roussy
|
|
| Description: |
| Patients: This Phase II study involved 70 patients with malignant pleural mesothelioma; 51 men and 19 women. Fifty-five patients had not received prior chemotherapy.
Treatment: The treatment consisted of the drug raltitrexed (tomudex) and the chemotherapy agent, oxaliplatin (eloxatin). Toxicity: Twenty patients withdrew from the treatment because of adverse events. There was one grade 4 event, asthenia. In addition, grade 3 toxicities included: nausea, paraesthesia, weight decrease, ALT and AST increase, vomiting, anorexia, hematologic, and abdominal pain. Results: Overall median survival was 32 weeks (7.4 months). Support: One or more of the study’s authors is affiliated with AstraZeneca, the manufacturer of tomudex. Correspondence: K. Fizazi, MD |
“My Name is Paul Kraus and I Have Survived Mesothelioma for Over 20 Years.”
In 1997 I was diagnosed with mesothelioma. The doctors gave me just a few short months to live...
But here I am, 20 years later, alive and well.
I wrote a book explaining how I became the longest living mesothelioma survivor in the world.
Today, I'd like to give you a copy for free because I want more people to survive this disease.
All you have to do is click the button below now. You will receive the book within 72 hours.
I wish you good health.
Sincerely,
"It has been over four years now and I can honestly say I am doing great. I highly recommend this book because it is inspirational and educational."